Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)

Journal of Infectious Diseases

Volumn 213, Issue 1, 2016, Pages 23-30

  Lischka, Peter ^a   Michel, Detlef ^b   Zimmermann, Holger ^a  

^a AiCuris GmbH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

antiviral drug resistance; cytomegalovirus; letermovir; AIC246; MK8228

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LETERMOVIR; PLACEBO; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; QUINAZOLINE DERIVATIVE; VIRUS DNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CYTOMEGALOVIRUS; OPEN READING FRAME; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; SEQUENCE ANALYSIS; STEM CELL TRANSPLANTATION; WILD TYPE; BLOOD; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GENETICS; PHASE 2 CLINICAL TRIAL; VIREMIA; VIROLOGY; VIRUS LOAD;

ACETATES; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HUMANS; OPEN READING FRAMES; QUINAZOLINES; VIRAL LOAD; VIREMIA;

EID: 84961989855     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv352     Document Type: Article

References (22)

1. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013; 13 (suppl 3): 24-40
2. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25: 151-69
3. Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015; 21: 24-9
4. Harter G, Michel D. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother 2012; 13: 623-7
5. Lischka P, Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008; 8: 541-8
6. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54: 1290-7
7. Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012; 56: 1135-7
8. Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. Genoand phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother 2014; 58: 610-3
9. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370: 1781-9
10. Stoelben S, Arns W, Renders L, et al. Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014; 27: 77-86
11. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884-93
12. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11: 1079-84
13. Griffiths PD, Emery VC. Taming the transplantation troll by targeting terminase. N Engl J Med 2014; 370: 1844-6
14. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689-712
15. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011; 24: 605-11
16. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190: 177-82
17. Goldner T, Zimmermann H, Lischka P. Phenotypic characterization of two naturally occurring human cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res 2015; 116C: 48-50
18. Yager TD, Baron L, Batra R, et al. High performance DNA sequencing, and the detection of mutations and polymorphisms, on the Clipper sequencer. Electrophoresis 1999; 20: 1280-300
19. Tischer BK, Von Einem J, Kaufer B, Osterrieder N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. BioTechniques 2006; 40: 191-7
20. Champier G, Couvreux A, Hantz S, et al. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther 2008; 13: 643-54
21. Pilorge L, Burrel S, Ait-Arkoub Z, Agut H, Boutolleau D. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. Antiviral Res 2014; 111: 8-12
22. Chevillotte M, Von Einem J, Meier BM, Lin FM, Kestler HA, Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res 2010; 85: 318-27